Venatorx Pharmaceuticals, Inc.

Microdose Therapeutx, Inc.

Viropharma Incorporated

Cytodyn Inc.

Microdose Therapeutix, Inc.

Daniel C Pevear

Christopher J Burns

Daniel McGarry

Robert E Lee Trout

Bin Liu

Denis Daigle

Randy W Jackson

Theodore John Nitz

David J Rys

Janet A Gaboury

Thomas A Lessen

Jodie Hamrick

Steven Armen Boyd

Ana Fernandez Casares

Timothy Henkel

Luigi Xerri

Lawrence Rosen

Sylvie Laguerre

Gerald Brenner

Jean-Baptiste Arlin

William C Olson

Paul J Maddon

Stephen M Condon

Guo-Hua Chu

Glen Coburn

Robert J Israel

Jose D Murga

Torsten Herbertz

Martin Seipel

Robert E Trout

Daniel Mcgarry

Allison L Zulli

Eugen F Mesaros

Sylvie Laquerre

Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.

Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

Orally-bioavailable nucleoside analogs

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Beta-lactamase inhibitors

This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 logto 2.5 logat about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 logat about nine days following administration of the CCR5 receptor antagonist.

Methods for reducing viral load in HIV-1 infected patients

Growing community of inventors

Downingtown, PA, United States of America

Daniel C Pevear